about
3'UTR-mediated gene silencing of the Mixed Lineage Leukemia (MLL) geneProteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistanceGSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesisTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesHijacked in cancer: the KMT2 (MLL) family of methyltransferasesThe role of aberrant proteolysis in lymphomagenesisA Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology.Disordered epigenetic regulation in MLL-related leukemia.A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency.Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaChromatin modifications as therapeutic targets in MLL-rearranged leukemia.Childhood B-acute lymphoblastic leukemia: a genetic update.A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.Developmentally induced Mll1 loss reveals defects in postnatal haematopoiesisSubstrate and product specificities of SET domain methyltransferasesDevelopment of a multi-step leukemogenesis model of MLL-rearranged leukemia using humanized miceTaspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.The molecular basis of myeloid malignancies.mll ortholog containing functional domains of human MLL is expressed throughout the zebrafish lifespan and in haematopoietic tissuesMLL fusions: pathways to leukemiaHigh-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.ConteXt of change--X inactivation and disease.HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.Linking MLL and the HGF-MET signaling pathway in liver cancer.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Transcriptional and epigenetic networks in haematological malignancy.The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.Chromosomal aberrations and fusion genes in myeloid malignancies.Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential.MicroRNAs mark in the MLL-rearranged leukemia.The promise and failures of epigenetic therapies for cancer treatmentMolecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.Hox gene dysregulation in acute myeloid leukemia.Mechanisms of mixed-lineage leukemia.Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.
P2860
Q21135144-12CF1C74-9E4C-4DA7-8D94-6575EFA8DF15Q24294703-39FE956B-B986-45E2-B9A4-613E9B48344AQ24300652-71E86A15-9F5C-4427-82CA-561802889230Q24319759-2F735583-1BA1-4685-AA29-8D0FCD84F80BQ26744441-95E3A4D0-5B08-4FAB-9DF7-F0F8DE5712C5Q27006839-7A14D336-5D3F-4D92-A782-690EECF061B4Q28084404-9DF6C9FE-B279-4095-AD4C-DAD9966241A3Q30401808-EA3E32C8-5DE5-4AA6-B652-24745EE4C2F4Q30422159-62C2695A-B291-4296-AD50-26219253FA58Q30494523-A8A5F11A-D1F8-4C36-971A-91095A764BD3Q30538418-DF3B0874-4FE9-4FDA-8DAA-6CC90FE5CDE7Q33666543-17CC8821-F51A-449A-8E57-BB6CC384BCFCQ33777616-18F1E653-2767-4892-98DA-C9CD46593EE1Q33943350-01B85FEC-C984-4DF9-9454-4DBF650344C8Q34195379-E5310FAA-37B0-4785-8582-519F02AA2F02Q34208487-FD4F544D-9ED7-43E1-9A72-143CCC5DECD1Q34321077-75EE974B-198F-496B-8BBC-C6948B54A09BQ34452426-DB82023B-A3CC-4184-A179-D4358D6BC48BQ34764504-FF3CD2A9-7AE2-4ACF-8BA8-FBAE6E478FEBQ35103708-B8672E08-505E-499A-8559-BAC83F338647Q35172438-91C6E27F-22DB-4A32-B3F2-A8AA7AF52E2CQ35788362-17F0CC0E-CE80-46EF-A5EB-051207AE573EQ35849281-F6F23370-6BEA-4FE2-A5E3-71D47388B481Q36039136-4A14BC69-2DA7-4BE3-A000-915AB64EF3F3Q36966973-DC51260F-ED1D-4779-88AB-8D36B0DDB0BEQ36967008-9E43D5D7-5A44-49DD-B38D-45CDE8141FA7Q37613872-758577E6-33A1-419E-88A9-57424016B887Q37821337-54019F78-7E51-417C-BF08-82223926E585Q37863271-1F724766-7E3D-412C-B48A-94B9DFCC8A06Q37874929-E66E51A4-5C3B-44B5-9B3B-ED8980777A14Q38044772-2D09AD7F-9E34-42BC-B6FA-7073A26D24EDQ38071556-5217F4CB-22AF-46F3-B23B-3979023C85D1Q38111235-E2E6F67A-17EC-41A2-90CC-0F66C7E67720Q38119782-B648D6B7-A3A5-47EA-94FF-D58A997D03C1Q38161393-BD0619AA-34EE-47F3-85D3-9805E25928CAQ38190116-0668F748-7CD6-4ED5-BD14-A350EFF6AFA7Q38190545-0D4A400C-972A-41C7-8311-28F1CB54B3F8Q38302235-782FBC2C-A44F-419A-A8F8-C0664ED6A88DQ38455086-90F7EF58-B2D0-4F79-BD26-33C91701D10AQ38753222-23FAD936-AE08-47C8-8BAF-6E8414005EED
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic targeting of MLL.
@en
Therapeutic targeting of MLL.
@nl
type
label
Therapeutic targeting of MLL.
@en
Therapeutic targeting of MLL.
@nl
prefLabel
Therapeutic targeting of MLL.
@en
Therapeutic targeting of MLL.
@nl
P2860
P1433
P1476
Therapeutic targeting of MLL.
@en
P2093
Michael L Cleary
Michaela Liedtke
P2860
P304
P356
10.1182/BLOOD-2008-12-197061
P407
P577
2009-03-16T00:00:00Z